[{"id":"a0f9dd51-d692-4574-b05e-3f5caa78cfd2","acronym":"AMPLIFY-201","url":"https://clinicaltrials.gov/study/NCT04853017","created_at":"2021-04-21T11:53:35.333Z","updated_at":"2024-07-02T16:35:09.637Z","phase":"Phase 1","brief_title":"A Study of ELI-002 in Subjects With KRAS Mutated Pancreatic Ductal Adenocarcinoma (PDAC) and Other Solid Tumors","source_id_and_acronym":"NCT04853017 - AMPLIFY-201","lead_sponsor":"Elicio Therapeutics","biomarkers":" KRAS • NRAS","pipe":" | ","alterations":" KRAS mutation • NRAS mutation • KRAS G12D • KRAS G12 • NRAS G12D • NRAS G12","tags":["KRAS • NRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • NRAS mutation • KRAS G12D • KRAS G12 • NRAS G12D • NRAS G12"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ELI-002 7P • Promune (agatolimod)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 25","initiation":"Initiation: 10/04/2021","start_date":" 10/04/2021","primary_txt":" Primary completion: 01/26/2023","primary_completion_date":" 01/26/2023","study_txt":" Completion: 03/01/2026","study_completion_date":" 03/01/2026","last_update_posted":"2024-04-15"},{"id":"acdeafe3-7008-41f0-8f96-f453b266a334","acronym":"","url":"https://clinicaltrials.gov/study/NCT01588015","created_at":"2021-01-18T06:46:27.904Z","updated_at":"2024-07-02T16:35:12.025Z","phase":"Phase 1","brief_title":"Vaccine Therapy in Preventing Cytomegalovirus Infection in Patients With Hematological Malignancies Undergoing Donor Stem Cell Transplant","source_id_and_acronym":"NCT01588015","lead_sponsor":"City of Hope Medical Center","biomarkers":" HLA-DRB1","pipe":" | ","alterations":" PD-1 expression","tags":["HLA-DRB1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Promune (agatolimod)"],"overall_status":"Completed","enrollment":" Enrollment 36","initiation":"Initiation: 10/29/2012","start_date":" 10/29/2012","primary_txt":" Primary completion: 02/02/2024","primary_completion_date":" 02/02/2024","study_txt":" Completion: 02/02/2024","study_completion_date":" 02/02/2024","last_update_posted":"2024-04-02"},{"id":"ab666c9a-6427-43ed-a474-52d69624f062","acronym":"","url":"https://clinicaltrials.gov/study/NCT00292045","created_at":"2021-01-27T22:52:15.081Z","updated_at":"2024-07-02T16:35:34.747Z","phase":"Phase 1","brief_title":"Immunization With NY-ESO-1 Protein Combined With CpG 7909 in Patients With Prostate Cancer","source_id_and_acronym":"NCT00292045","lead_sponsor":"Ludwig Institute for Cancer Research","biomarkers":" CD8 • CTAG1B","pipe":"","alterations":" ","tags":["CD8 • CTAG1B"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Promune (agatolimod)"],"overall_status":"Completed","enrollment":" Enrollment 15","initiation":"Initiation: 10/27/2004","start_date":" 10/27/2004","primary_txt":" Primary completion: 01/09/2006","primary_completion_date":" 01/09/2006","study_txt":" Completion: 01/09/2006","study_completion_date":" 01/09/2006","last_update_posted":"2023-10-04"},{"id":"acb324c0-7ea9-4e70-8f73-9c5486bc513d","acronym":"","url":"https://clinicaltrials.gov/study/NCT00199836","created_at":"2021-01-18T00:40:44.608Z","updated_at":"2024-07-02T16:36:02.794Z","phase":"Phase 1","brief_title":"A Pilot Study of NY-ESO-1b Peptide Plus CpG 7909 and Montanide® ISA-51 in Patients With Cancer.","source_id_and_acronym":"NCT00199836","lead_sponsor":"Ludwig Institute for Cancer Research","biomarkers":" CD8 • CTAG1B • CTAG2","pipe":" | ","alterations":" HLA-A2 positive","tags":["CD8 • CTAG1B • CTAG2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HLA-A2 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Promune (agatolimod)"],"overall_status":"Completed","enrollment":" Enrollment 14","initiation":"Initiation: 09/03/2003","start_date":" 09/03/2003","primary_txt":" Primary completion: 09/05/2005","primary_completion_date":" 09/05/2005","study_txt":" Completion: 06/06/2006","study_completion_date":" 06/06/2006","last_update_posted":"2022-10-10"},{"id":"cd953313-4922-4eb7-86f4-86fd680fb3b5","acronym":"","url":"https://clinicaltrials.gov/study/NCT00299728","created_at":"2021-01-18T01:01:31.071Z","updated_at":"2024-07-02T16:36:02.802Z","phase":"Phase 1","brief_title":"NY-ESO-1 Protein With Montanide and CpG 7909 as Cancer Vaccine in Several Tumors","source_id_and_acronym":"NCT00299728","lead_sponsor":"Ludwig Institute for Cancer Research","biomarkers":" CTAG1B • CD4 • CTAG2","pipe":" | ","alterations":" CTAG1B expression • CTAG2 expression","tags":["CTAG1B • CD4 • CTAG2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CTAG1B expression • CTAG2 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Promune (agatolimod)"],"overall_status":"Completed","enrollment":" Enrollment 22","initiation":"Initiation: 03/21/2006","start_date":" 03/21/2006","primary_txt":" Primary completion: 10/10/2006","primary_completion_date":" 10/10/2006","study_txt":" Completion: 01/10/2014","study_completion_date":" 01/10/2014","last_update_posted":"2022-10-10"},{"id":"e3c3481a-4a24-4334-a6f6-ce5a4ce224dc","acronym":"","url":"https://clinicaltrials.gov/study/NCT01266603","created_at":"2021-01-18T05:07:17.231Z","updated_at":"2025-02-25T13:16:31.595Z","phase":"Phase 2","brief_title":"High-Dose Interleukin-2 (HDIL-2), Combined With recMAGE-A3 + AS15 ASCI","source_id_and_acronym":"NCT01266603","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" MAGEA3","pipe":"","alterations":" ","tags":["MAGEA3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Proleukin (aldesleukin) • Promune (agatolimod) • Zumagev (astuprotimut-R)"],"overall_status":"Completed","enrollment":" Enrollment 44","initiation":"Initiation: 02/22/2011","start_date":" 02/22/2011","primary_txt":" Primary completion: 11/01/2018","primary_completion_date":" 11/01/2018","study_txt":" Completion: 11/01/2018","study_completion_date":" 11/01/2018","last_update_posted":"2020-02-19"},{"id":"78f9ae56-1ab1-4142-b708-00048fc5dda4","acronym":"","url":"https://clinicaltrials.gov/study/NCT00490529","created_at":"2021-01-29T06:57:12.785Z","updated_at":"2024-07-02T16:36:51.441Z","phase":"Phase 2","brief_title":"Phase 1-2 of a CpG-Activated Whole Cell Vaccine Followed by Autologous Immunotransplant for MCL","source_id_and_acronym":"NCT00490529","lead_sponsor":"Ronald Levy","biomarkers":" CD4","pipe":"","alterations":" ","tags":["CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rituxan (rituximab) • cyclophosphamide • Neupogen (filgrastim) • Promune (agatolimod) • cyclophosphamide intravenous"],"overall_status":"Completed","enrollment":" Enrollment 59","initiation":"Initiation: 08/01/2009","start_date":" 08/01/2009","primary_txt":" Primary completion: 12/14/2017","primary_completion_date":" 12/14/2017","study_txt":" Completion: 12/14/2017","study_completion_date":" 12/14/2017","last_update_posted":"2020-01-13"},{"id":"90fb6027-621c-4dc6-9ea8-cc3e46aa43e2","acronym":"","url":"https://clinicaltrials.gov/study/NCT00819806","created_at":"2021-02-16T02:52:12.218Z","updated_at":"2024-07-02T16:37:19.374Z","phase":"Phase 1","brief_title":"CpG 7909/Montanide ISA 720 With or Without Cyclophosphamide in Combination Either With NY-ESO-1-derived Peptides or the NY-ESO-1 Protein for NY-ESO-1-expressing Tumors","source_id_and_acronym":"NCT00819806","lead_sponsor":"Hassane M. Zarour, MD","biomarkers":" CTAG1B","pipe":" | ","alterations":" CTAG1B expression","tags":["CTAG1B"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CTAG1B expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • Promune (agatolimod) • cyclophosphamide intravenous"],"overall_status":"Completed","enrollment":" Enrollment 21","initiation":"Initiation: 01/01/2009","start_date":" 01/01/2009","primary_txt":" Primary completion: 05/01/2012","primary_completion_date":" 05/01/2012","study_txt":" Completion: 01/01/2015","study_completion_date":" 01/01/2015","last_update_posted":"2017-07-31"}]